---
title: "CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CDNA Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294561699.md"
description: "CareDx, Inc. announced inducement grants under Nasdaq Listing Rule 5635(c)(4). On July 30, 2026, the company granted Executive Advisor James McNally 15,822 restricted stock units (RSUs) as an inducement for his employment. The awards follow the 2025 Inducement Equity Incentive Plan, with 50% vesting on January 2, 2027, and the remaining 50% on July 2, 2027, contingent on continued service."
datetime: "2026-07-31T14:45:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294561699.md)
  - [en](https://longbridge.com/en/news/294561699.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294561699.md)
generator: "portal-rs"
---

# CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CDNA Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 30, 2026, CareDx granted to James McNally, the Company’s newly appointed Executive Advisor, certain stock awards as an inducement material to Mr. McNally’s employment with CareDx.

CareDx granted 15,822 shares of common stock restricted stock units (RSUs) to Mr. McNally. The RSU awards were made pursuant to the Company’s 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

50% of the RSUs will vest on January 2, 2027, and 50% will vest on July 2, 2027 subject to the employee’s continued service through each vesting date.

CareDx is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

**About CareDx**

CareDx is a leading precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, CareDx is dedicated to improving patient outcomes. For more information, please visit www.caredx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260731951215/en/

CareDx  
Media Contacts  
Natasha Moshirian Wagner  
nwagner@caredx.com

Investor Relations  
Nina Deka  
investor@caredx.com

Source: CareDx, Inc.

### Related Stocks

- [CDNA.US](https://longbridge.com/en/quote/CDNA.US.md)

## Related News & Research

- [CareDx Stock Is Up 300% Over the Past Year. Here’s How Much Upside Is Left.](https://longbridge.com/en/news/295446013.md)
- [CareDx Q2 revenue beats estimates; outlook lifted](https://longbridge.com/en/news/294409121.md)
- [Wrap Technologies (NASDAQ: WRAP) Selected to Support Florida Teacher Safety Training Program](https://longbridge.com/en/news/296129490.md)
- [Amazon Thinks AI Is About to Change the Way We Shop. Goodbye, Search Bar.](https://longbridge.com/en/news/296251288.md)
- [$1000 Invested In Veeco Instruments 5 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296657245.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**